Klaus Brischwein

1.9k total citations
21 papers, 1.5k citations indexed

About

Klaus Brischwein is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Klaus Brischwein has authored 21 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 14 papers in Radiology, Nuclear Medicine and Imaging and 9 papers in Molecular Biology. Recurrent topics in Klaus Brischwein's work include Monoclonal and Polyclonal Antibodies Research (14 papers), CAR-T cell therapy research (12 papers) and Glycosylation and Glycoproteins Research (4 papers). Klaus Brischwein is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (14 papers), CAR-T cell therapy research (12 papers) and Glycosylation and Glycoproteins Research (4 papers). Klaus Brischwein collaborates with scholars based in Germany, Switzerland and United States. Klaus Brischwein's co-authors include Patrick A. Baeuerle, Peter Kufer, Bernd Schlereth, Robert Hofmeister, Patrick Hoffmann, Nadja Prang, Ralf C. Bargou, Christian Brandl, Christian Itin and Mathias Locher and has published in prestigious journals such as Cancer Research, FEBS Letters and British Journal of Cancer.

In The Last Decade

Klaus Brischwein

20 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Klaus Brischwein Germany 17 1.1k 728 582 451 146 21 1.5k
Bernd Schlereth Germany 14 994 0.9× 832 1.1× 622 1.1× 432 1.0× 62 0.4× 23 1.4k
Stefan Knackmuss Germany 23 660 0.6× 640 0.9× 485 0.8× 534 1.2× 34 0.2× 41 1.4k
Ezogelin Oflazoglu United States 18 809 0.8× 727 1.0× 703 1.2× 463 1.0× 18 0.1× 23 1.7k
Sonja Offner Germany 8 641 0.6× 329 0.5× 309 0.5× 496 1.1× 33 0.2× 8 1.1k
Julie A. McEarchern United States 13 537 0.5× 294 0.4× 384 0.7× 387 0.9× 24 0.2× 25 1.0k
Christina Krupka Germany 13 861 0.8× 198 0.3× 594 1.0× 398 0.9× 121 0.8× 25 1.3k
Enkhtsetseg Purev United States 21 755 0.7× 129 0.2× 308 0.5× 768 1.7× 75 0.5× 55 1.6k
Paul Balderes United States 18 397 0.4× 381 0.5× 173 0.3× 736 1.6× 19 0.1× 32 1.2k
LH Shapiro United States 8 466 0.4× 138 0.2× 178 0.3× 822 1.8× 81 0.6× 9 1.3k
Jun-Ping Wei United States 19 425 0.4× 157 0.2× 366 0.6× 657 1.5× 41 0.3× 41 1.2k

Countries citing papers authored by Klaus Brischwein

Since Specialization
Citations

This map shows the geographic impact of Klaus Brischwein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaus Brischwein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaus Brischwein more than expected).

Fields of papers citing papers by Klaus Brischwein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaus Brischwein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaus Brischwein. The network helps show where Klaus Brischwein may publish in the future.

Co-authorship network of co-authors of Klaus Brischwein

This figure shows the co-authorship network connecting the top 25 collaborators of Klaus Brischwein. A scholar is included among the top collaborators of Klaus Brischwein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klaus Brischwein. Klaus Brischwein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Haas, Cornelia, Klaus Brischwein, Patrick Hoffmann, et al.. (2009). Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology. 214(6). 441–453. 144 indexed citations
2.
Amann, Maria, Grit Lorenczewski, Klaus Brischwein, et al.. (2009). Antitumor Activity of an EpCAM/CD3-bispecific BiTE Antibody During Long-term Treatment of Mice in the Absence of T-cell Anergy and Sustained Cytokine Release. Journal of Immunotherapy. 32(5). 452–464. 43 indexed citations
3.
Amann, Maria, Matthias Friedrich, Petra Lutterbuese, et al.. (2008). Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans. Cancer Immunology Immunotherapy. 58(1). 95–109. 30 indexed citations
4.
Schlereth, Bernd, Klaus Brischwein, H. Winter, et al.. (2008). Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110. Breast Cancer Research and Treatment. 117(3). 471–481. 16 indexed citations
5.
Baeuerle, Patrick A., Maria Amann, Klaus Brischwein, et al.. (2007). Therapeutic window of MuS110, a single-chain antibody construct bispecific for EpCAM (CD326) and CD3. Molecular Cancer Therapeutics. 6. 3 indexed citations
6.
Brandl, Christian, Cornelia Haas, Tanja Fisch, et al.. (2007). The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunology Immunotherapy. 56(10). 1551–1563. 103 indexed citations
7.
Haas, Cornelia, Klaus Brischwein, Matthias Friedrich, et al.. (2007). Mode of action of MT110, a novel bispecific single-chain antibody construct of the BiTE class for treatment of adeno and squamous cell carcinoma expressing EpCAM (CD326). 6. 1 indexed citations
8.
Brischwein, Klaus, Stefan Pflanz, Jörg Volkland, et al.. (2007). Strictly Target Cell-dependent Activation of T Cells by Bispecific Single-chain Antibody Constructs of the BiTE Class. Journal of Immunotherapy. 30(8). 798–807. 146 indexed citations
9.
Lutterbuese, Petra, Klaus Brischwein, Robert Hofmeister, et al.. (2006). Exchanging human Fcγ1 with murine Fcγ2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model. Cancer Immunology Immunotherapy. 56(4). 459–468. 10 indexed citations
10.
Mølhøj, Michael, Klaus Brischwein, Doris Rau, et al.. (2006). CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Molecular Immunology. 44(8). 1935–1943. 77 indexed citations
11.
Schlereth, Bernd, Iduna Fichtner, Grit Lorenczewski, et al.. (2005). Eradication of Tumors from a Human Colon Cancer Cell Line and from Ovarian Cancer Metastases in Immunodeficient Mice by a Single-Chain Ep-CAM-/CD3-Bispecific Antibody Construct. Cancer Research. 65(7). 2882–2889. 101 indexed citations
12.
Brischwein, Klaus, Bernd Schlereth, Andreas Wolf, et al.. (2005). MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Molecular Immunology. 43(8). 1129–1143. 212 indexed citations
13.
Prang, Nadja, et al.. (2005). Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. British Journal of Cancer. 92(2). 342–349. 123 indexed citations
14.
Hoffmann, Patrick, Robert Hofmeister, Klaus Brischwein, et al.. (2005). Serial killing of tumor cells by cytotoxic T cells redirected with a CD19‐/CD3‐bispecific single‐chain antibody construct. International Journal of Cancer. 115(1). 98–104. 264 indexed citations
15.
Schlereth, Bernd, Petra Kleindienst, Iduna Fichtner, et al.. (2005). Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3. Cancer Immunology Immunotherapy. 55(7). 785–796. 44 indexed citations
16.
Sonnemann, Jürgen, Volker Gekeler, Katrin Ahlbrecht, et al.. (2004). Down-regulation of protein kinase Cη by antisense oligonucleotides sensitises A549 lung cancer cells to vincristine and paclitaxel. Cancer Letters. 209(2). 177–185. 34 indexed citations
17.
Brischwein, Klaus, Chao Liu, Peter Bader, et al.. (2003). Induction of drug resistance and protein kinase C genes in A2780 ovarian cancer cells after incubation with antineoplastic agents at sublethal concentrations.. PubMed. 22(6C). 4229–32. 23 indexed citations
18.
19.
Brischwein, Klaus, et al.. (1997). Role of Ribonucleotide Reductase and Deoxynucleotide Pools in the Oxygen‐Dependent Control of DNA Replication in Ehrlich Ascites Cells. European Journal of Biochemistry. 244(2). 286–293. 24 indexed citations
20.
Gekeler, Volker, et al.. (1993). Staurosporine suppresses replicon initiation in mammalian cells. FEBS Letters. 327(2). 150–156. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bernd Schlereth Breakdown of academic impact, for papers by Stefan Knackmuss Breakdown of academic impact, for papers by Ezogelin Oflazoglu Breakdown of academic impact, for papers by Sonja Offner Breakdown of academic impact, for papers by Julie A. McEarchern Breakdown of academic impact, for papers by Christina Krupka Breakdown of academic impact, for papers by Enkhtsetseg Purev Breakdown of academic impact, for papers by Paul Balderes Breakdown of academic impact, for papers by LH Shapiro Breakdown of academic impact, for papers by Jun-Ping Wei
Rankless by CCL
2026